Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose transporter type 9 (GLUT9, encoded by the SLC2A9 gene) is a facilitative membrane transporter primarily expressed in the kidneys, liver, and other epithelia. It exists as two main splice variants, GLUT9a and GLUT9b, which differ in cellular localization. It is unique among glucose transporters for its high-capacity transport of urate (uric acid) in addition to hexose sugars such as glucose and fructose. In the kidney, GLUT9 regulates serum uric acid by reabsorbing urate from the renal tubules into the blood; it also participates in glucose handling. Mutations in SLC2A9 can cause renal hypouricemia or predispose to gout, and altered GLUT9 function has been implicated in obesity, metabolic syndrome, and chronic kidney diseases. No drugs are known to directly target GLUT9, but it is mechanistically linked to the action of uricosuric drugs. Serum uric acid concentration can serve as a biomarker of its function or dysfunction. Dysregulation presents safety concerns involving uric acid metabolism, such as risk of kidney stones or gout.
Inhibition or modulation of urate reabsorption/excretion (for drugs that might target GLUT9)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucose transporter type 9 (GLUT9).